Company: DVAX
Filing Date: 2025-05-07
Form Type: DEFA14A
Source: 0000930413-25-001671
Chunk: 5

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-07
Form: DEFA14A
Chunk 5
---
 the risk that circumstances surrounding or leading up to our 2025 Annual Meeting may change,
risks relating to our ability to commercialize and supply HEPLISAV-B, the risks that market size or actual demand for our products
may differ from our expectations, risks related to the timing of completion and results of current clinical studies, risks related
to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, and risks related to the implementation
of our long-term growth objectives, as well as other risks detailed in the “Risk Factors” section of our Quarterly
Report on Form 10-Q for the three months ended March 31, 2025 and any periodic filings made thereafter, as well as discussions
of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission.
These forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and
we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new
information becomes available. Information on Dynavax’s website at www.dynavax.com is not incorporated by reference in our
current periodic reports with the SEC.

Important Additional Information and Where to Find It

On April 17, 2025, the Company filed a definitive proxy statement
on Schedule 14A (the “Proxy Statement”) and form of accompanying GOLD proxy card with the U.S. Securities and Exchange
Commission (the “SEC”) in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company’s
director nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding
its solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other
document that the Company has filed or may file with the SEC in connection with any solicitation by the Company. STOCKHOLDERS
OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING GOLD PROXY CARD AND OTHER RELEVANT DOCUMENTS
FILED WITH, OR FURNISHED TO, THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. Stockholders may obtain
a copy of the Proxy Statement, accompanying GOLD proxy card, any amendments or supplements to the Proxy Statement and any other
relevant documents filed by the Company with the SEC